Literature DB >> 8032216

Mutation and expression of the p53 gene in human malignant melanoma.

A P Albino1, M J Vidal, N S McNutt, C R Shea, V G Prieto, D M Nanus, J M Palmer, N K Hayward.   

Abstract

Derangement of the p53 tumor suppressor gene has been implicated in the aetiology of a wide range of human neoplasias. We have previously determined that overexpression and mutation of the p53 gene in cultured metastatic melanomas is low (11%). However, two recent immunohistochemical studies have reported that > 85% of malignant melanoma specimens overexpress mutated p53 protein. In an effort to resolve this contradiction in the published literature, we have re-evaluated a range of cultured and non-cultured melanocytic lesions for the occurrence of point mutations in the p53 gene using DNA- and RNA-dependent single strand conformation polymorphism (RNA-SSCP) and direct DNA sequencing of polymerase chain reaction (PCR) amplified DNA, and overexpression of the p53 protein using immunohistochemistry. We found point mutations in 25% (9 of 36) of cultured melanomas and 0% in 34 fresh melanoma biopsies; however, increased p53 expression was found in 42% of paraffin-embedded melanoma specimens and 7% of benign lesions. The low frequency of p53 point mutations and high frequency of p53 expression suggests that derangement of the p53 gene by point mutations is not a common perturbation in the majority of melanoma cells, and that overexpression of p53 in this tumour type is due to a mechanism other than point mutation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032216     DOI: 10.1097/00008390-199402000-00006

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  32 in total

1.  The potential role of DFNA5, a hearing impairment gene, in p53-mediated cellular response to DNA damage.

Authors:  Yoshiko Masuda; Manabu Futamura; Hiroki Kamino; Yasuyuki Nakamura; Noriaki Kitamura; Shiho Ohnishi; Yuji Miyamoto; Hitoshi Ichikawa; Tsutomu Ohta; Misao Ohki; Tohru Kiyono; Hiroshi Egami; Hideo Baba; Hirofumi Arakawa
Journal:  J Hum Genet       Date:  2006-08-02       Impact factor: 3.172

2.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

4.  p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.

Authors:  Yang Ou; Shang-Jui Wang; Le Jiang; Bin Zheng; Wei Gu
Journal:  J Biol Chem       Date:  2014-11-17       Impact factor: 5.157

5.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.

Authors:  Yakov Chudnovsky; Amy E Adams; Paul B Robbins; Qun Lin; Paul A Khavari
Journal:  Nat Genet       Date:  2005-06-12       Impact factor: 38.330

Review 6.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 7.  Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Authors:  Grant M Fischer; Y N Vashisht Gopal; Jennifer L McQuade; Weiyi Peng; Ralph J DeBerardinis; Michael A Davies
Journal:  Pigment Cell Melanoma Res       Date:  2017-11-02       Impact factor: 4.693

8.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

9.  Survivin repression by p53, Rb and E2F2 in normal human melanocytes.

Authors:  Deepak Raj; Tong Liu; George Samadashwily; Fengzhi Li; Douglas Grossman
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

10.  Reduced Apaf-1 expression in human cutaneous melanomas.

Authors:  D L Dai; M Martinka; J A Bush; G Li
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.